Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Netherlands-based biopharmaceutical firm Lanthio Pharma has received an Innovation Credit loan of about €3.6m by Dutch Government agency RVO for the development of new therapy for lung fibrosis.
Subscribe to our email newsletter
The loan will support the development of LP2, the first peptide-based drug , for treatment of Idiopathic Pulmonary Fibrosis.
LP2 is an innovative lanthipeptide used to activate the Angiotensin type 2 (AT2) receptor of the Renin Angiotensin System (RAS).
Natural role of the AT2 receptor is to protect damaged tissue against inflammation and fibrosis.
The company said that once safety and efficacy of LP2 is established in Idiopathic Pulmonary Fibrosis patients, application of LP2 could be extended to many other forms of fibrosis, including renal fibrosis, heart fibrosis and liver fibrosis.
The loan made available to stimulate innovative drug development in The Netherlands is risk bearing and will be matched by the company’s investors.
The loan covers about 35% of development costs through to completion of Phase II human Proof of Concept trials.
Lanthio Pharma CEO Bart Wuurman said the company is happy with this support by the Dutch Government to help them develop its fibrosis drug.
"We are keen to show that LP2 is effective against Idiopathic Pulmonary Fibrosis, a life threatening disease for which effective treatments are not yet available," Wuurman said.